SCHEMBL25830774

SCHEMBL25830774

CC(C)(C)OC(=O)N1CCN(c2ccc3[nH]c4ncnc(Cl)c4c3c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 3/20 0.53
KIT P10721 2/20 0.52
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
MAP4K4 O95819 1/20 0.43
POLB P06746 1/20 0.43
PDK2 Q15119 1/20 0.42
NAMPT P43490 1/20 0.42
CCNK O75909 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31017638 1.00 ALK (0.53) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL31017632 0.84 ALK (0.55) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL25830759 0.84 ALK (0.55) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL26969676 0.80 ALK (0.57) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL31560094 0.80 ALK (0.57) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL16535580 0.80 KIT (0.68) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL23852078 0.78 MKNK1 (0.51) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL25232158 0.77 KIT (0.49) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL23852725 0.76 ALK (0.59) ALKKITMAPTSMN1; SMN2MEN1
SCHEMBL25094482 0.76 KIT (0.55) KITMAPTSMN1; SMN2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366770-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 US disclosed
WO-2023125907-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366770-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, LYN ALK 1141/4885KIT 1478/4885MAPT 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.